What's in Universidad Complutense de Madrid's pipeline?

Universidad Complutense de Madrid has 16 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 4 in Phase 2, 4 in Phase 1.

Which companies overlap with Universidad Complutense de Madrid's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Bayer, GlaxoSmithKline, Medical University of Vienna, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidad-complutense-de-madrid.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Universidad Complutense de Madrid — Portfolio Competitive Intelligence Brief

Universidad Complutense de Madrid pipeline: 8 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 4 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
70% alcohol	70% alcohol	marketed
Antiinflammatories	Antiinflammatories	marketed			Other
70% alcohol - 0.5% clorhexidine	70% alcohol - 0.5% clorhexidine	marketed
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases	Infectious Disease
Emdogain (EMD) - test	Emdogain (EMD) - test	marketed	Regenerative biologic / Enamel matrix derivative	Enamel matrix proteins (EMPs); indirect effects on growth factors and cell signaling pathways	Dentistry / Periodontics
Application of Enamel Matrix Derivatives	Application of Enamel Matrix Derivatives	marketed	Regenerative biologic / Periodontal regenerative material	Amelogenins and associated enamel matrix proteins	Dentistry / Periodontics
Hand antisepsis by scrub	Hand antisepsis by scrub	marketed			Infection Prevention / Surgical Prophylaxis
NBF	NBF	marketed	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Dentistry / Periodontics · 2
Diabetes · 1
Infection Prevention / Surgical Prophylaxis · 1
Infectious Disease · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Bayer · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Medical University of Vienna · 2 shared drug classes
Pfizer · 2 shared drug classes
Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad Complutense de Madrid:

Cite this brief

Drug Landscape (2026). Universidad Complutense de Madrid — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-complutense-de-madrid. Accessed 2026-05-16.